Pfizer splitting operations into three units

Pfizer CEO Ian Read

Pfizer ($PFE) is doing some reorganization--the company said Monday that it would split its operations into three distinct units, two focused on "innovative" drugs and a third including so-called "value" business. After Pfizer was praised by investors when it sold off its nutrition unit to Nestlé and spun off its animal health business Zoetis, Pfizer CEO Ian Read said he'd consider breaking up the pharma giant into smaller units. Each new Pfizer unit will be headed by a group president. More

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.